Institute of Science Tokyo · International Research Institute for Medical-Engineering Collaboration · 特任講師

Research keywordsCell・Endoplasmic・Molecular・RNA結合タンパク質・biology・タンパク質凝集・核酸医薬・筋萎縮性側索硬化症（ALS）

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Kuroiwa N, Sakaue F, Miura M, Go A, Iwase R, Iwata Hara R, Sanjo N, Ui-Tei K, Yokota T. Rational Design of a Multivalent RNA Combining Structural Motifs Tailored to Multiple Domains of Fused in Sarcoma for Potent Inhibition of Aggregation. Chembiochem : a European journal of chemical biology. 2026.04; 27 (8): e202500568. ( PubMed , DOI )2026
• Matsuda-Kawabata S, Nagata T, Yanagidaira M, Ihara K, Ohyagi M, Kaburagi H, Yoshida-Tanaka K, Sasaki A, Abe A, Ebihara S, Hasegawa J, Toide N, Ohara M, Naito M, Miyata K, Toh K, Sakaue F, Yokota T. Heteroduplex oligonucleotide technology boosts gene knockdown in cardiac and skeletal muscles. Nucleic acids research. 2026.01; 54 (3): ( PubMed , DOI )2026
• Hasegawa J, Nagata T, Ihara K, Tanihata J, Ebihara S, Yoshida-Tanaka K, Yanagidaira M, Ohara M, Sasaki A, Nakayama M, Yamamoto S, Ishii T, Iwata-Hara R, Naito M, Miyata K, Sakaue F, Yokota T. Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model. Nature communications. 2024.09; 15 (1): 7530. ( PubMed , DOI )2024
• Miura M, Sakaue F, Matsuno H, Morita K, Yoshida A, Hara RI, Nishimura R, Nishida Y, Yokogawa M, Osawa M, Yokota T. TDP-43 N-terminal domain dimerisation or spatial separation by RNA binding decreases its propensity to aggregate. FEBS letters. 2023.05; 597 (12): 1667-1676. ( PubMed , DOI )2023

• ALSモデルマウスの表現型を改善する核酸医薬の開発
• 中枢神経系へのデリバリーが可能なムコ多糖症新規治療薬の探索
• TDP-43タンパク質を標的とした孤発性筋萎縮性側索硬化症の核酸医薬開発
• 細胞外tsRNAを介したミスフォールディングタンパク質伝播メカニズムの解明

• Official profile